Methods of treating inflammation using antibodies to M-CSF

Details Methods of treating inflammation using antibodies to M-CSF Methods of treating inflammation using antibodies to M-CSF

2006-09-19

2006-09-19

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S184100, C424S141100

Reexamination Certificate

active

07108852

ABSTRACT:
A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

REFERENCES:
patent: 4504586 (1985-03-01), Nicholson et al.
patent: 4847201 (1989-07-01), Kaswasaki et al.
patent: 4868119 (1989-09-01), Clark et al.
patent: 4929700 (1990-05-01), Halenbeck et al.
patent: 5470569 (1995-11-01), Kawasaki et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5491065 (1996-02-01), Halenbeck et al.
patent: 5573763 (1996-11-01), Clark et al.
patent: 5643563 (1997-07-01), Ladner et al.
patent: 5681719 (1997-10-01), Ladner et al.
patent: 5792450 (1998-08-01), Wilson et al.
patent: 5837229 (1998-11-01), Ralph et al.
patent: 5837460 (1998-11-01), Von Feldt et al.
patent: 6103224 (2000-08-01), Ladner et al.
patent: 6117422 (2000-09-01), Ladner et al.
patent: 6146851 (2000-11-01), Ladner et al.
patent: 6204020 (2001-03-01), Ladner et al.
patent: 6322779 (2001-11-01), Halenbeck et al.
patent: WO 91/08774 (1991-06-01), None
patent: WO00/09561 (2000-02-01), None
patent: WO 2004/045532 (2004-06-01), None
Van Noort et al. International Review of Cytology, 1998.
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Ngo et al, iThe Protein Folding Problem and Tertiary Structure Prediction, 1994. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Mestas et al J. of Immunology, 2004, 172, pp. 2731-2738.
Janeway et al. Immunobiology, Third Edition, 1999, pp. 650-651.
Bischof, R.J.,et al., Clin Exp Immunol 2000; 119: pp. 361-367.
Cook, A. D. et al., Arthritis Res 2001, 3: pp. 293-298.
Campbell, I. K et al., The Journal of Immunology, 1998, V 161 pp. 3639-3644.
Verdrengh M. and Tarkowski A., Infection and Immunity, Feb. 1998. pp. 853-855.
McQualter, J. L., J. Exp. Med, vol. 194, No. 7, Oct. 1, 2001, pp. 873-881.
Aharinejad, S. Cancer Research 62, Sep. 15, 2002, pp. 5317-5324.
Campbell, I. K., Journal of Leukocyte Biology, vol. 68, Jul. 2000, pp. 144-150.
M. Feldman et al., “Anti-TNF α Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases”, Transplantation Proceedings 1998, 30:4126-4127.
R.O. Williams et al., “Anti-Tumor Necrosis Factor Ameliorates Joint Disease in Murine Collagen-Induced Arthritis”, Proc. Natl. Acad. Sci. USA Immunology 1992, 89:9784-9788.
Handschumacher (1990), Drugs Used for Immunosuppression , pp. 1264-1276, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition, Gilman et al. (eds.), Pergamon Press, New York.
Terato, Kuniaki, et al, “Collagen-Induced Arthritis in Mice: Synergistic Effect ofE. ColiLipopolysaccharide Bypasses Epitope Specificity in the Induction of Arthritis with Monoclonal Antibodies to Type II Collagen”, Autoimmunity, 1995, vol. 22, pp. 137-147.
Terato, Kuniaki, et al, “Induction of Arthritis with Monoclonal Antibodies to Collagen”, Journal of Immunilogy, vol. 148, No. 7, 1992, pp. 2103-2108.
Abstract of JP 05095794.
Abstract of JP 06194367.
Abstract of JP 06319584.
Metcalf, D., The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells, Nature, May 4, 1989, vol. 339, 27-30.

Affiliated with

Also associated with

Rating

Methods of treating inflammation using antibodies to M-CSF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating inflammation using antibodies to M-CSF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating inflammation using antibodies to M-CSF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3590699